The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Initial sequencing and analysis of the human genome
International Human Genome Sequencing Consortium, Whitehead Institute for Biomedical Research, C. F. G. R., Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J., Devon, K., Dewar, K., et al. (2001) · Nature · doi:10.1038/35057062 · Cited by 24,216
The sequence of the human genome
Venter, J. C., Adams, M. D., Myers, E. W., Li, P. W., Mural, R. J., Sutton, G. G., Smith, H. O., Yandell, M., Evans, C. A., Holt, R. A., et al. (2001) · Science · doi:10.1126/science.1058040 · Cited by 13,909
Self-citationShimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785
Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics
Evans, W. E., & Relling, M. V. (1999) · Science · doi:10.1126/science.286.5439.487 · Cited by 2,475
Self-citationLehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T., & Kliewer, S. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci3703 · Cited by 1,576
Characterization of single-nucleotide polymorphisms in coding regions of human genes
Cargill, M., Altshuler, D., Ireland, J., Sklar, P., Ardlie, K., Patil, N., Lane, C. R., Lim, E. P., Kalyanaraman, N., Nemesh, J., et al. (1999) · Nature Genetics · doi:10.1038/10290 · Cited by 1,547
The molecular biology of cytochrome P450s
Gonzalez, F. J. (1988) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00021-3 · Cited by 1,301
Variations on a Theme: Cataloging Human DNA Sequence Variation
Collins, F. S., Guyer, M. S., & Chakravarti, A. (1997) · Science · doi:10.1126/science.278.5343.1580 · Cited by 1,050
Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis
Halushka, M. K., Fan, J.-B., Bentley, K., Hsie, L., Shen, N., Weder, A., Cooper, R., Lipshutz, R., & Chakravarti, A. (1999) · Nature Genetics · doi:10.1038/10297 · Cited by 1,012
Rendic, S., & Carlo, F. J. D. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709037591 · Cited by 949
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Calcineurin Inhibitor Nephrotoxicity
Naesens, M., Kuypers, D. R. J., & Sarwal, M. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.04800908 · Cited by 1,489
Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478
Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Weinshilboum, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020021 · Cited by 1,031
Genetic contribution to variable human CYP3A-mediated metabolism
Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00066-2 · Cited by 990
Self-citationClinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation
Staatz, C. E., & Tett, S. E. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443100-00001 · Cited by 913
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Zhou, S.-F., Liu, J.-P., & Chowbay, B. (2009) · Drug Metabolism Reviews · doi:10.1080/03602530902843483 · Cited by 826
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
Moving towards individualized medicine with pharmacogenomics
Evans, W. E., & Relling, M. V. (2004) · Nature · doi:10.1038/nature02626 · Cited by 768
Self-citationUGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity
Iyer, L., Das, S., Janisch, L., Wen, M., Ramírez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., & Ratain, M. J. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500072 · Cited by 720
Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
Brunet, M., van Gelder, T., Åsberg, A., Haufroid, V., Hesselink, D. A., Langman, L., Lemaitre, F., Marquet, P., Seger, C., Shipkova, M., et al. (2019) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000640 · Cited by 707
Potential Role of Pharmacogenomics in Reducing Adverse Drug Reactions: A Systematic Review
Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K., & Sadee, W. (2001) · JAMA · doi:10.1001/jama.286.18.2270 · Cited by 705
The genetic determinants of the CYP3A5 polymorphism
Hustert, E., Haberl, M., Burk, O., Wolbold, R., He, Y.-Q., Klein, K., Nuessler, A. C., Neuhaus, P., Klattig, J., Eiselt, R., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200112000-00005 · Cited by 673
Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J.-P., Decosterd, L. A., Furrer, H., Opravil, M., Pantaleo, G., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07276-8 · Cited by 658
Hesselink, D. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00168-1 · Cited by 655
Cytochrome P450-mediated metabolism of estrogens and its regulation in human
Tsuchiya, Y., Nakajima, M., & Yokoi, T. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.10.007 · Cited by 616
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Zanger, U. M., Turpeinen, M., Klein, K., & Schwab, M. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-2291-6 · Cited by 593
Zhou, Y., Ingelman‐Sundberg, M., & Lauschke, V. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.690 · Cited by 583
Cytochrome P450 pharmacogenetics and cancer
Rodriguez-Antona, C., & Ingelman-Sundberg, M. (2006) · Oncogene · doi:10.1038/sj.onc.1209377 · Cited by 575
Sex Is A Major Determinant of Cyp3a4 Expression in Human Liver
Wolbold, R., Klein, K., Burk, O., Nüssler, A. K., Neuhaus, P., Eichelbaum, M., Schwab, M., & Zanger, U. M. (2003) · Hepatology · doi:10.1002/hep.1840380424 · Cited by 529
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., & McLeod, H. L. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544030-00005 · Cited by 517
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
Wang, D., Guo, Y., Wrighton, S. A., Cooke, G. E., & Sadee, W. (2011) · The Pharmacogenomics Journal · doi:10.1038/tpj.2010.28 · Cited by 505
Self-citationThe toxicology of aflatoxins as a basis for public health decisions
Wild, C. P. (2002) · Mutagenesis · doi:10.1093/mutage/17.6.471 · Cited by 475
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.883 · Cited by 471
Self-citationWallemacq, P., Armstrong, V. W., Brunet, M., Haufroid, V., Holt, D. W., Johnston, A., Kuypers, D., Meur, Y. L., Marquet, P., Oellerich, M., et al. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318198d092 · Cited by 468
Pharmacogenetics, Pharmacogenomics, and Individualized Medicine
Ma, Q., & Lu, A. Y. H. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003533 · Cited by 464
Lee, A. J., Cai, M. X., Thomas, P. E., Conney, A. H., & Zhu, B. T. (2003) · Endocrinology · doi:10.1210/en.2003-0192 · Cited by 456
How Important Are Gender Differences in Pharmacokinetics?
Meibohm, B., Beierle, I., & Derendorf, H. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241050-00002 · Cited by 454
Co-Regulation of CYP3A4 and CYP3A5 and Contribution to Hepatic and Intestinal Midazolam Metabolism
Lin, Y. S., Dowling, A. L. S., Quigley, S. D., Farin, F. M., Zhang, J., Lamba, J., Schuetz, E. G., & Thummel, K. E. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.1.162 · Cited by 449
Self-citationHaufroid, V., Mourad, M., Van Kerckhove, V., Wawrzyniak, J., De Meyer, M., Eddour, D. C., Malaise, J., Lison, D., Squifflet, J.-P., & Wallemacq, P. (2004) · Pharmacogenetics · doi:10.1097/00008571-200403000-00002 · Cited by 447
Luo, G., Cunningham, M., Kim, S., Burn, T., Lin, J., Sinz, M., Hamilton, G., Rizzo, C., Jolley, S., Gilbert, D., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.7.795 · Cited by 442
Pharmacogenomics: The Inherited Basis for Interindividual Differences in Drug Response
Evans, W. E., & Johnson, J. A. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.9 · Cited by 415
The ontogeny of drug metabolism enzymes and implications for adverse drug events
Hines, R. N. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.02.005 · Cited by 410
Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice
Gardiner, S. J., & Begg, E. J. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.6 · Cited by 406
Lamba, V., Lamba, J., Yasuda, K., Strom, S., Davila, J., Hancock, M. L., Fackenthal, J. D., Rogan, P. K., Ring, B., Wrighton, S. A., et al. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.054866 · Cited by 400
Self-citationPharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine
Ahmed, S., Zhou, Z., Zhou, J., & Chen, S.-Q. (2016) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.03.008 · Cited by 371
Developmental Expression of the Major Human Hepatic CYP3A Enzymes
Stevens, J. C., Hines, R. N., Gu, C., Koukouritaki, S. B., Manro, J. R., Tandler, P. J., & Zaya, M. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.054841 · Cited by 368
The Ontogeny of Human Drug-Metabolizing Enzymes: Phase I Oxidative Enzymes
Hines, R. N., & McCarver, D. G. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.355 · Cited by 365
Caraco, Y., Blotnick, S., & Muszkat, M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100316 · Cited by 360
NIEMI, M., BACKMAN, J., KAJOSAARI, L., LEATHART, J., NEUVONEN, M., DALY, A., EICHELBAUM, M., KIVISTO, K., & NEUVONEN, P. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.01.018 · Cited by 360
Self-citationPharmGKB: The Pharmacogenomics Knowledge Base
Thorn, C. F., Klein, T. E., & Altman, R. B. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-435-7_20 · Cited by 358
Dai, D., Tang, J., Rose, R., Hodgson, E., Bienstock, R. J., Mohrenweiser, H. W., & Goldstein, J. A. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29199-0 · Cited by 357
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms
Ingelman-Sundberg, M. (2004) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-003-0819-z · Cited by 353
Staatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317550-000000000-00000 · Cited by 343
Cytochrome P450-mediated metabolism in the human gut wall
Thelen, K., & Dressman, J. B. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.05.0002 · Cited by 338
Staatz, C. E., Goodman, L. K., & Tett, S. E. (2010) · Clinical Pharmacokinetics · doi:10.2165/11317350-000000000-00000 · Cited by 336
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced Cancer
Goetz, M. P., Toft, D., Reid, J., Ames, M., Stensgard, B., Safgren, S., Adjei, A. A., Sloan, J., Atherton, P., Vasile, V., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.119 · Cited by 336
Ontogeny of Hepatic and Renal Systemic Clearance Pathways in Infants: Part I
Alcorn, J., & McNamara, P. J. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00003 · Cited by 333
CYP3A Variation and the Evolution of Salt-Sensitivity Variants
Thompson, E. E., Kuttab-Boulos, H., Witonsky, D., Yang, L., Roe, B. A., & Di Rienzo, A. (2004) · The American Journal of Human Genetics · doi:10.1086/426406 · Cited by 331
Pharmacogenetics of warfarin: current status and future challenges
Wadelius, M., & Pirmohamed, M. (2007) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500417 · Cited by 330
Transcriptional Control of Intestinal Cytochrome P-4503A by 1α,25-Dihydroxy Vitamin D3
Thummel, K. E., Brimer, C., Yasuda, K., Thottassery, J., Senn, T., Lin, Y., Ishizuka, H., Kharasch, E., Schuetz, J., & Schuetz, E. (2001) · Molecular Pharmacology · doi:10.1124/mol.60.6.1399 · Cited by 325
Self-citationde Leon, J., Susce, M. T., Pan, R.-M., Fairchild, M., Koch, W. H., & Wedlund, P. J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0103 · Cited by 319
Common allelic variants of cytochrome P4503A4 and their prevalence in different populations
Lamba, J. K., Lin, Y. S., Thummel, K., Daly, A., Watkins, P. B., Strom, S., Zhang, J., & Schuetz, E. G. (2002) · Pharmacogenetics · doi:10.1097/00008571-200203000-00006 · Cited by 316
Self-citationMacphee, I. A. M., Fredericks, S., Tai, T., Syrris, P., Carter, N. D., Johnston, A., Goldberg, L., & Holt, D. W. (2002) · Transplantation · doi:10.1097/00007890-200212150-00002 · Cited by 315
Interindividual Variability and Tissue-Specificity in the Expression of Cytochrome P450 3A mRNA
Koch, I., Weil, R., Wolbold, R., Brockmöller, J., Hustert, E., Burk, O., Nuessler, A., Neuhaus, P., Eichelbaum, M., Zanger, U., et al. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.10.1108 · Cited by 314
CYP3A5 Variant Allele Frequencies in Dutch Caucasians
van Schaik, R. H., van der Heiden, I. P., van den Anker, J. N., & Lindemans, J. (2002) · Clinical Chemistry · doi:10.1093/clinchem/48.10.1668 · Cited by 306
Genetic Variability in CYP3A5 and its Possible Consequences
Xie, H.-G., Wood, A. J., Kim, R. B., Stein, C. M., & Wilkinson, G. R. (2004) · Pharmacogenomics · doi:10.1517/phgs.5.3.243.29833 · Cited by 302
The genetic basis of variability in drug responses
Roden, D. M., & George Jr, A. L. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd705 · Cited by 292
The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates
Cotreau, M. M., von Moltke, L. L., & Greenblatt, D. J. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544010-00002 · Cited by 292
Zhang, J., Kuehl, P., Green, E. D., Touchman, J. W., Watkins, P. B., Daly, A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., et al. (2001) · Pharmacogenetics · doi:10.1097/00008571-200110000-00003 · Cited by 292
Self-citationWegman, P., Elingarami, S., Carstensen, J., Stål, O., Nordenskjöld, B., & Wingren, S. (2007) · Breast Cancer Research · doi:10.1186/bcr1640 · Cited by 288
Islands of linkage disequilibrium
Goldstein, D. B. (2001) · Nature Genetics · doi:10.1038/ng1001-109 · Cited by 286
Tamoxifen Resistance in Breast Cancer
Chang, M.-S. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.3.256 · Cited by 285
Sachse, C. (2002) · Carcinogenesis · doi:10.1093/carcin/23.11.1839 · Cited by 284
Use and Application of Stem Cells in Toxicology
Davila, J. C. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh100 · Cited by 281
EFFECT OF CYP3A5 POLYMORPHISM ON TACROLIMUS METABOLIC CLEARANCE IN VITRO
Dai, Y., Hebert, M. F., Isoherranen, N., Davis, C. L., Marsh, C., Shen, D. D., & Thummel, K. E. (2006) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.008680 · Cited by 279
Self-citationP-Glycoprotein Increases from Proximal to Distal Regions of Human Small Intestine
Mouly, S., & Paine, M. F. (2003) · Pharmaceutical Research · doi:10.1023/a:1026183200740 · Cited by 276
Functional Gene Variants of CYP3A4
Werk, A. N., & Cascorbi, I. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.129 · Cited by 273
Goh, B.-C., Lee, S.-C., Wang, L.-Z., Fan, L., Guo, J.-Y., Lamba, J., Schuetz, E., Lim, R., Lim, H.-L., Ong, A.-B., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.01.025 · Cited by 270
Self-citationPharmacokinetics in the newborn
Alcorn, J., & McNamara, P. J. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00030-9 · Cited by 266
Patki, K. C., von Moltke, L. L., & Greenblatt, D. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.7.938 · Cited by 263
Floyd, M. D., Gervasini, G., Masica, A. L., Mayo, G., George, A. L., Bhat, K., Kim, R. B., & Wilkinson, G. R. (2003) · Pharmacogenetics · doi:10.1097/00008571-200310000-00003 · Cited by 261
Westlind-Johnsson, A., Malmebo, S., Johansson, A., Otter, C., Andersson, T. B., Johansson, I., Edwards, R. J., Boobis, A. R., & Ingelman-Sundberg, M. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.6.755 · Cited by 258
MacPhee, I. A. M., Fredericks, S., Tai, T., Syrris, P., Carter, N. D., Johnston, A., Goldberg, L., & Holt, D. W. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00435.x · Cited by 258
Haas, D. W., Smeaton, L. M., Shafer, R. W., Robbins, G. K., Morse, G. D., Labbé, L., Wilkinson, G. R., Clifford, D. B., D’Aquila, R. T., De Gruttola, V., et al. (2005) · The Journal of Infectious Diseases · doi:10.1086/497610 · Cited by 257
PharmGKB summary: cyclosporine and tacrolimus pathways
Barbarino, J. M., Staatz, C. E., Venkataramanan, R., Klein, T. E., & Altman, R. B. (2013) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e328364db84 · Cited by 257
Self-citationL??tsch, J., Skarke, C., Liefhold, J., & Geisslinger, G. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443140-00003 · Cited by 256
von Richter, O., Burk, O., Fromm, M. F., Thon, K. P., Eichelbaum, M., & Kivistö, K. T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.10.008 · Cited by 255
Significance of the Minor Cytochrome P450 3A Isoforms
Daly, A. K. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645010-00002 · Cited by 254
Self-citationKnockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism
van Herwaarden, A. E., Wagenaar, E., van der Kruijssen, C. M. M., van Waterschoot, R. A. B., Smit, J. W., Song, J.-Y., van der Valk, M. A., van Tellingen, O., van der Hoorn, J. W. A., Rosing, H., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci33435 · Cited by 235
Achour, B., Barber, J., & Rostami-Hodjegan, A. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058834 · Cited by 212
Alternative Splicing Regulates the Subcellular Localization of Divalent Metal Transporter 1 Isoforms
Tabuchi, M., Tanaka, N., Nishida-Kitayama, J., Ohno, H., & Kishi, F. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-03-0165 · Cited by 141
Andrews, L. M., Li, Y., De Winter, B. C. M., Shi, Y.-Y., Baan, C. C., Van Gelder, T., & Hesselink, D. A. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1395413 · Cited by 142
Variability of CYP3A7 expression in human fetal liver
Leeder, J. S., Gaedigk, R., Marcucci, K. A., Gaedigk, A., Vyhlidal, C. A., Schindel, B. P., & Pearce, R. E. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.086504 · Cited by 136
Polymorphisms affecting gene regulation and mRNA processing: Broad implications for pharmacogenetics
JOHNSON, A., WANG, D., & SADEE, W. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.11.001 · Cited by 97
Trofe-Clark, J., Brennan, D. C., West-Thielke, P., Milone, M. C., Lim, M. A., Neubauer, R., Nigro, V., & Bloom, R. D. (2018) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2017.07.018 · Cited by 93
Thishya, K., Vattam, K. K., Naushad, S. M., Raju, S. B., & Kutala, V. K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191921 · Cited by 65
Song, Q.-Q., Xie, W.-Y., Tang, Y.-J., Zhang, J., & Liu, J. (2017) · Pharmacogenomics · doi:10.2217/pgs-2016-0151 · Cited by 40
Self-citationWojtyniak, J., Selzer, D., Schwab, M., & Lehr, T. (2021) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2111 · Cited by 38
Impact of CYP3A5 genotype on de-novo LCP tacrolimus dosing and monitoring in kidney transplantation
Rao, N., Carcella, T., Patel, N., Bartlett, F., Posadas, M. A., Casey, M., Dubay, D. A., & Taber, D. J. (2023) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000494 · Cited by 5
Metadata
- Authors
- Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., Watkins, P. B., Daly, A., Wrighton, S. A., Hall, S. D., Maurel, P., Relling, M., Brimer, C., Yasuda, K., Venkataramanan, R., Strom, S., Thummel, K., Boguski, M. S., & Schuetz, E.
- Venue
- Nature Genetics
- Published
- 2001-04
- Volume
- 27
- Issue
- 4
- Pages
- 383-391
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2105902511
- Cited by
- 2,162
- References
- 43
- FWCI
- 76.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.